Celcuity Inc(CELC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 17 at 6:19 PM ET (Korea 9/18 07:19)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.3 | Insider Own | 17.66% | Shs Outstand | 48.9M | Perf Week | -0.68% |
| Market Cap | 4.15B | Forward P/E | - | EPS next Y | 65.82% | Insider Trans | -26.63% | Shs Float | 40.3M | Perf Month | -8.93% |
| Enterprise Value | 4.16B | PEG | - | EPS next Q | -1.4 | Inst Own | 103.6% | Short Float | 26.53% | Perf Quarter | -3.57% |
| Income | -0.23B | P/S | - | EPS this Y | -28.39% | Inst Trans | 21.65% | Short Ratio | 8.81 | Perf Half Y | -24.53% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -44.77% | Short Interest | 10.69M | Perf YTD | -14.87% |
| Book/sh | -0.26 | P/C | 5.51 | EPS past 3/5Y | -13.08% -32.62% | ROE | -1433.7% | 52W High | -43.78% ($151.02) | Perf Year | 55.51% |
| Cash/sh | 15.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -30.55% | 52W Low | 91.15% ($44.42) | Perf 3Y | 715.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -24.72% | Gross Margin | - | Volatility(W/M) | 3.96% 4.01% | Perf 5Y | 312.59% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.93 | EPS Q/Q | -38.76% | Profit Margin | - | RSI (14) | 41.85 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.93 | Sales Q/Q | - | SMA20 | -5.61% ($89.96) | Beta | 0.12 | Target Price | $160.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -6.77% ($91.08) | Rel Volume | 0.57 | Prev Close | $82.58 |
| Employees | 155 | LT Debt/Eq | - | EPS/Sales Surpr. | -23.66% - | SMA200 | -19.66% ($105.69) | Avg Volume(3M) | 1.21M | Price | $84.91 |
| IPO | 2017/9/20 | Option/Short | Yes/Yes | Trades | 9611 | Volume | 692,146 | Change | 2.82% |
Company
CELC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A clinical-stage biotech company developing targeted therapies for breast cancer. Its lead candidate, gedatolisib, is a targeted therapy aimed at hormone receptor-positive breast cancer, which has shown positive results in Phase 3 clinical trials and has advanced to the new drug application stage. This is a breast cancer drug developer approaching commercialization.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
CELC has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -28.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +715.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 103.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SBIO 0.04%
CANC 0.04%
PTH 0.03%
DWAS 0.01%
XBI 0.01%It ranks #4 in the industry
Based on market cap of $4B.
CELC $4B PER -
VRTX $131B PER 30.0
REGN $81B PER 19.5
MRNA $63B PER -
FAQ
What kind of company is CELC?
CELC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CELC?
The market cap of CELC is approximately $4.2B, ranking 1,522 within its sector.
What is the 52-week high and low for CELC?
CELC has recorded a 52-week high of $151.02 and a low of $44.42.
